Carboplatin Injection shortage
Carboplatin Injection is currently listed in shortage by the FDA. The FDA lists 35 affected products. The reported reason: Other; Discontinuation of the manufacture of the drug; Demand increase for the drug. This page was last refreshed from FDA data on Oct 2, 2026.
Carboplatin injection is currently in shortage, with some strengths and vial sizes unavailable from certain manufacturers. Most common strengths are still listed by makers not reporting a shortage, though supply has been tight for over a year.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Carboplatin Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Oct 1, 2026Currently in shortage35 of 35 products affected.
-
Sep 22, 2026FDA refreshed this shortage record8 products updated.
-
Sep 17, 2026FDA refreshed this shortage record2 products updated.
-
Sep 16, 2026FDA refreshed this shortage record4 products updated.
-
Sep 15, 2026FDA refreshed this shortage record10 products updated.
-
Sep 1, 2026FDA refreshed this shortage record2 products updated.
-
Jun 1, 2026FDA refreshed this shortage record4 products updated.
-
Jun 1, 2026More presentations reported4 more products added to the shortage.
-
Feb 20, 2026FDA refreshed this shortage record2 products updated.
-
Feb 20, 2026More presentations reported2 more products added to the shortage.
-
Apr 28, 2023First reported to the FDA29 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Accord Healthcare Inc. 📞 866-941-7875, option 2 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31) | — | Unavailable | Estimated recovery: TBD | Discontinuation of the manufacture of the drug |
| Current | Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33) | — | Unavailable | Estimated recovery: TBD | Discontinuation of the manufacture of the drug |
| Current | Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34) | — | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... |
| Current | Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12) | — | Unavailable | Estimated recovery: TBD | Requirements related to complying with good manufacturing pr... |
Manufacturer: Avyxa Pharma, LLC 📞 877-595-7337; [email protected] 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08) | — | Available | — | — |
| Current | Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50) | — | Available | — | — |
Manufacturer: Eugia US LLC 📞 888-238-7880 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01) | — | Unavailable | On backorder. Recovery: late October 2026. Check wholesalers for inventory | Demand increase for the drug |
| Current | Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01) | — | Available | Check wholesalers for inventory | — |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60) | — | Unavailable | Next release November 2026. Check wholesalers for inventory. | Delay in shipping of the drug |
Manufacturer: Gland Pharma Limited 📞 Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01) | — | Limited Availability | Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC | Demand increase for the drug |
| Current | Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01) | — | Available | Distributed by BPI Labs, LLC | — |
| Current | Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01) | — | Limited Availability | Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC | Demand increase for the drug |
| Current | Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01) | — | Unavailable | Discontinued; Distributed by BPI Labs, LLC | Discontinuation of the manufacture of the drug |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 8 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05) | — | Unavailable | Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05) | — | Unavailable | Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50) | — | Limited Availability | Limited Supply Available. Next Delivery and Estimated Recovery: December 2026 | Demand increase for the drug |
| Current | Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18) | — | Unavailable | Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18) | — | Limited Availability | Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027 | Demand increase for the drug |
| Current | Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56) | — | Limited Availability | Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05) | — | Unavailable | Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22) | — | Limited Availability | Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other |
Manufacturer: Ingenus Pharmaceuticals LLC 📞 866-321-5031 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45) | — | — | Discontinuation of the manufacture of the drug | — |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01) | — | Limited Availability | Estimated recovery: February 2027 | Other |
| Current | Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01) | — | Limited Availability | Estimated recovery: December 2028 | Other |
| Current | Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01) | — | Unavailable | Estimated recovery: January 2027 | Other |
| Current | Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01) | — | Limited Availability | Estimated recovery: September 2027 | Other |
Manufacturer: Teyro Labs 📞 Apotex Inc.: 800-706-5575 8 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) | — | Unavailable | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug |
| Current | Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) | — | Unavailable | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug |
| Current | Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) | — | Unavailable | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug |
| Current | Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) | — | Unavailable | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug |
| To Be Discontinued | Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) | — | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) | — | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) | — | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) | — | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Carboplatin Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Carboplatin Injection? options further down this page.
Why is Carboplatin Injection in shortage?
The carboplatin injection shortage is being driven by several different problems happening at the same time across multiple manufacturers. Accord Healthcare has had to stop shipping certain vials of their 10 mg/mL concentration due to issues meeting FDA manufacturing quality standards, and a no-return date has been set yet. Some of Accord's other packages of the same strength have been permanently discontinued. Teyro Labs (marketed through Apotex Inc.) has permanently stopped making all of their carboplatin sizes — the 50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL, and 600 mg/60 mL vials. Gland Pharma has also permanently discontinued their 50 mg/5 mL size.
On top of those permanent stops, there are factory production delays and shipping hold-ups affecting other makers. Fresenius Kabi's 10 mg/mL vials have a shipping delay, with the next release expected in November 2026. Hospira (Pfizer) is dealing with manufacturing delays across several sizes — their 600 mg/60 mL has limited supply with recovery expected around September–December 2026, their 150 mg/15 mL recovery is projected around December 2026–March 2027, and their 50 mg/5 mL and 450 mg/45 mL recoveries are estimated around December 2026–March 2027. Eugia's 450 mg/45 mL is on backorder due to higher-than-usual demand, with recovery expected in late October 2026. Notably, Eugia's 600 mg/60 mL and Gland Pharma's 150 mg/15 mL are currently reported as available from those manufacturers.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Carboplatin Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Carboplatin Injection?
Carboplatin injection is currently on the FDA drug-shortage list. This is a chemotherapy medicine given in a clinic or hospital, and your care team manages the supply for you — so the practical steps here are mostly handled by the pharmacy and prescriber.
Several strengths still have an available source, including the 150 mg/15 mL and 600 mg/60 mL vials from certain makers. Other strengths currently have no available source, including some multiple-dose vials (50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL, and 600 mg/60 mL) and the 50 mg/5 mL single vial, which one manufacturer has discontinued. The 450 mg/45 mL is on backorder, with recovery reported around late October 2026.
The FDA lists several reasons, including manufacturing and shipping delays, higher demand, and some products being discontinued. Importantly, 5 of 9 manufacturers still report supply, so this affects only certain makers — not every source.
- Do not skip or delay any treatment on your own — your care team is tracking this.
- Ask your clinic whether your strength is still available and can be ordered through wholesalers or another manufacturer.
- The same medicine is still listed from Teva and Eugia; your pharmacy may be able to source one of these, though it may not be in local stock.
- If your exact strength is discontinued, ask your prescriber about a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference. This is general, national data and may not match your clinic's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Carboplatin Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Carboplatin Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Carboplatin | CARBOPLATIN 10 mg/mL | Injection, Solution · Intravenous | Teva Parenteral Medicines, Inc. | 00703-4239-81 |
| Carboplatin | CARBOPLATIN 450 mg/45mL | Injection, Solution · Intravenous | Eugia US LLC | 55150-0335-00 |
| Carboplatin | CARBOPLATIN 600 mg/60mL | Injection, Solution · Intravenous | Eugia US LLC | 55150-0386-00 |
Therapeutic equivalents & pricing 30 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| CARBOplatin 10 mg/mL | Teva | 1 vial | — | AP | FDA listed |
| CARBOplatin 10 mg/mL | Teva | 1 vial | — | AP | FDA listed |
| CARBOplatin 10 mg/mL | Teva | 1 vial | — | AP | FDA listed |
| CARBOplatin 10 mg/mL | Teva | 1 vial | — | AP | Discontinued |
| Carboplatin 10 mg/mL | Accord | 1 vial | — | — | FDA listed |
| Carboplatin 10 mg/mL | BPI | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | BPI | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | BPI | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | BPI | 1 vial | — | AP | FDA listed |
| Carboplatin 50 mg/5mL | Eugia | 1 vial | — | AP | FDA listed |
| Carboplatin 150 mg/15mL | Eugia | 1 vial | — | AP | FDA listed |
| Carboplatin 450 mg/45mL | Eugia | 1 vial | — | AP | FDA listed |
| Carboplatin 600 mg/60mL | Eugia | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | Apotex | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | Hospira, | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | Hospira, | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | Hospira, | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | Hospira, | 1 vial | — | AP | Discontinued |
| Carboplatin 10 mg/mL | Hospira, | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | Fresenius | 1 vial | — | — | FDA listed |
| Carboplatin 10 mg/mL | Gland | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | Gland | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | Gland | 1 vial | — | AP | FDA listed |
| Carboplatin 10 mg/mL | Gland | 1 vial | — | AP | FDA listed |
| Carboplatin 50 mg/5mL | Teyro | 1 vial | — | AP | FDA listed |
| Carboplatin 150 mg/15mL | Teyro | 1 vial | — | AP | FDA listed |
| Carboplatin 450 mg/45mL | Teyro | 1 vial | — | AP | FDA listed |
| Carboplatin 600 mg/60mL | Teyro | 1 vial | — | AP | FDA listed |
| Kyxata 80 mg/8mL | Avyxa | 1 vial | — | — | FDA listed |
| Kyxata 500 mg/50mL | Avyxa | 1 vial | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Carboplatin Injection — that fall in the same broad treatment class (antineoplastic - alkylating agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other oncology shortages
Carboplatin Injection shortage FAQs
Is Carboplatin Injection in shortage?
Why is Carboplatin Injection in shortage?
Which products are affected?
When will Carboplatin Injection be available again?
Can I still get Carboplatin somewhere?
What should I do if I take Carboplatin Injection?
Still have a question about the Carboplatin Injection shortage?
Ask a pharmacist about this shortage →View Carboplatin Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.